Text Size

Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00846560
First received: February 15, 2009
Last updated: February 17, 2009
Last verified: February 2009
History of Changes
  Purpose

The involvement of Lymphocyte type B in Amyotrophic lateral sclerosis (ALS) patients will be compared to lymphocyte in healthy subjects.


Condition
Amyotrophic Lateral Sclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment: 20
Study Start Date: August 2008
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1 ALS patients
2 Healthy subjects

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Amyotrophic lateral sclerosis and Healthy subjects

Criteria

Inclusion Criteria:

  • ALS patients who could sign ICF.

Exclusion Criteria:

  • No ALS patients age less than 18 years.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00846560

Locations
Israel
Rambam Medical center, Neurology Department
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
  More Information

No publications provided

Responsible Party: Prof. David Yarnitsky, Rambam medical center
ClinicalTrials.gov Identifier: NCT00846560     History of Changes
Other Study ID Numbers: ALS04CTIL
Study First Received: February 15, 2009
Last Updated: February 17, 2009
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Sclerosis
Motor Neuron Disease
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
 Neurodegenerative Diseases
TDP-43 Proteinopathies
Neuromuscular Diseases
Proteostasis Deficiencies
Metabolic Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on September 26, 2012